Clinical trials: Myotonic Dystrophy 2
Pulmonary Tuberculosis, Diabetes Mellitus, Type 2
Joint Management of DM2 and Pulmonary TB in Orizaba, Veracruz
The objective of this study is to evaluate an integral strategy in which diabetes mellitus 2 (DM2) and pulmonary tuberculosis (TB) are managed together.
- Trial name
- NCT03277742
- Testing
- Community intervention, Standard of care
- Where
- Mexico
- Sponsor
- Instituto Nacional de Salud Publica, Mexico
Diabetes Mellitus, Type 2
Anti-inflammatory Status in DM2 Treated Patients
Diabetes mellitus Type 2 (DMT2) - a progressive insulin secretory defect on the background of insulin resistance - is one of the major risk factors for atherosclerosis, an inflammatory disease of the arterial wall, in which…
- Trial name
- INF-DM2-Ther (NCT04392557)
- Testing
- Metformin / alogliptin Oral Product, Metformin / Pioglitazone Pill, triple therapy
- Where
- Italy
- Volunteers
- 36 people
- Sponsor
- University of Catanzaro
Diabetes Mellitus, Type 2, Surgical Site Infection
Postoperative Basal Bolus or Sliding Scale Insulin Regimen in DM2 and Its Effect on Surgical Site Infections.
A multicentre, matched-pair, cluster randomised controlled superiority trial to investigate the effect of a proactive basal bolus insulin regimen compared to the reactive sliding scale insulin regimen, targeting a glucose level…
- Trial name
- GUIDE (NCT06638567)
- Testing
- Basal bolus insulin regimen
- Where
- Netherlands
- Volunteers
- 1,008 people
- Sponsor
- Abraham Hulst, MD, PhD
Diabetes Mellitus 2 Type
Comparison of Two Insulin Regimens in Optimally-controlled Patients With DM2.
Intensive Insulin Therapy (IIT) may be given in Type 2 Diabetes (T2DM) in two different ways : as Basal/bolus therapy (B/B) in four-five injections per day . as Modern Premixed Insulins( MPI's) three times per day .
- Trial name
- NCT01627509
- Where
- 2 sites in Israel
- Volunteers
- 40 people
- Sponsor
- Sheba Medical Center
Diabetes Mellitus, Type 2
Cinnamomum Cassia Effect on IGF1 and Metabolic Control in Patients With DM2 Without Glycemic Control Metformin Treated
Among the multiple treatment options for Diabetes Mellitus Type 2 (DM2), the influence on Insuline like growth factor 1 (IGF1) plays a causal role in diabetes but has shown similarities with insulin, both in its structure and in…
- Trial name
- CICAFAC1 (NCT03610412)
- Testing
- Cinnamomum Cassia
- Where
- Mexico
- Volunteers
- 28 people
- Sponsor
- Coordinación de Investigación en Salud, Mexico
Myotonic Dystrophy, Facioscapulohumeral Muscular Dystrophy
Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
Myotonic dystrophy (DM) and facioscapulohumeral muscular dystrophy (FSHD) are inherited disorders characterized by progressive muscle weakness and loss of muscle tissue.
- Conditions
- Myotonic Dystrophy, Facioscapulohumeral Muscular Dystrophy, Muscular Dystrophy, Myotonic Dystrophy Type 1
- Trial name
- NCT00082108
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Type 2 Diabetes
Research on Effects of Drugs on Body Composition and Function With Imaging in Diabetes
One downside of diabetes weight loss drugs like GLP-1RA and GLP-1RA/GIP, is that they can cause muscle loss, which is especially risky for older adults or those already prone to frailty and falls.
- Trial name
- REBUILD (NCT07156331)
- Volunteers
- 20 people
- Sponsor
- Kristin Clemens
Diabete Mellitus
CGM to Aid Transition From Inpatient to Outpatient
A pilot study using the FreeStyle Libre to assess its potential benefits in patients with diabetes starting when they are inpatients and continuing during the transition of care to the outpatient setting to see if diabetes care…
- Trial name
- NCT03155594
- Testing
- Freestyle Libre
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Methodist Medical Center of Illinois
Diabetes Mellitus, Type 2, Hypoglycemia
Continuous Glucose Monitoring Devices in Hospitalized Veterans With Diabetes
More than 25% of the patients admitted in the general wards have a history of Diabetes Mellitus (DM). Up to 30% of the hospitalized diabetics develop hypoglycemia (low glucose values); a condition that is associated with…
- Trial name
- NCT03508934
- Testing
- GTS (Continuous Glucose Monitoring), POC (Point of Care)
- Where
- United States
- Volunteers
- 218 people
- Sponsor
- VA Office of Research and Development
DM1, Myotonic Dystrophy 1
Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients
AOC 1001-CS1 is a randomized, double-blind, placebo-controlled, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple-doses of AOC 1001 Administered Intravenously to…
- Conditions
- DM1, Myotonic Dystrophy 1, Myotonic Dystrophy, Myotonic Dystrophy Type 1 (DM1)
- Trial name
- MARINA (NCT05027269)
- Testing
- AOC 1001
- Where
- 8 sites in United States
- Volunteers
- 39 people
- Sponsor
- Avidity Biosciences, Inc.
Type 2 Diabetes Mellitus (T2DM)
BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes
The goal of this clinical trial is to evaluate the efficacy and safety of Bofanglutide (GZR18) compared with Semaglutide in Latin American adults with type 2 diabetes mellitus who have inadequate glycemic control while receiving…
- Trial name
- NCT07628985
- Testing
- Bofanglutide, Semaglutide
- Where
- 7 sites in Mexico
- Volunteers
- 374 people
- Sponsor
- Carnot Laboratories
Myotonic Dystrophy
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed MEX-DM-302 Study.
This is an open-label extension study intended to evaluate the long-term safety and efficacy of mexiletine PR in patients with myotonic dystrophy type 1 and type 2 (DM1 and DM2) who have completed the parent study MEX-DM-302.
- Trial name
- NCT06549400
- Testing
- Mexiletine granules for prolonged-release oral suspension
- Where
- 6 sites in Belgium, Denmark and 4 more
- Volunteers
- 176 people
- Sponsor
- Lupin Ltd.
Weight Loss, Metabolic Syndrome
Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)
The use of continuous glucose monitoring (CGM) in earlier data has inspired behavioral changes leading to improved adherence to an exercise plan in individuals and eating habits in people with diabetes.
- Conditions
- Weight Loss, Metabolic Syndrome, Diabetes Mellitus, Type 2, Central Obesity
- Trial name
- NCT05874635
- Testing
- Continuous Glucose Monitor Device
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Signos Inc
Myotonic Dystrophy Type 1 (DM1)
A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VX-670 at different single and multiple doses in participants with DM1.
- Trial name
- Galileo (NCT06185764)
- Testing
- VX-670
- Where
- 26 sites in United States, Australia and 8 more
- Volunteers
- 47 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Type 2 Diabetes Mellitus, Medical Education
Generative AI-Based Simulation for Diagnostic Communication in Type 2 Diabetes (DIALOGUE-DM2)
This randomized controlled trial evaluates the effectiveness of a generative artificial intelligence (AI)-based simulation program in improving diagnostic communication skills among medical students.
- Conditions
- Type 2 Diabetes Mellitus, Medical Education, Diagnostic Communication, Artificial Intelligence Simulation
- Trial name
- DIALOGUE-DM2 (NCT07252193)
- Testing
- AI-Based Simulation Training (DIALOGUE-DM2), Traditional Training
- Where
- Mexico
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Universidad Nacional Autonoma de Mexico
Type2 Diabetes
A Study to Assess the Effect of Psyllium vs. Wheat Dextrin on Glycemic Control and Inflammatory Markets in Diabetes Mellitus 2
The purpose of this study is to determine which of Psyllium and Wheat Dextrin is more effective in lowering fasting blood sugar and hemoglobin A1c, and to evaluate the effects they have on laboratory values.
- Trial name
- NCT04547790
- Testing
- Psyllium, Wheat Dextrin
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Mayo Clinic
DM1, Muscular Dystrophies
Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients
AOC 1001-CS2 (MARINA-OLE) (NCT05479981) is a Phase 2 extension of the AOC 1001-CS1 (MARINA) (NCT05027269) study to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of multiple-doses of AOC 1001…
- Conditions
- DM1, Muscular Dystrophies, Myotonic Dystrophy, Myotonic Dystrophy 1
- Trial name
- MARINA-OLE (NCT05479981)
- Testing
- AOC 1001
- Where
- 8 sites in United States
- Volunteers
- 37 people
- Sponsor
- Avidity Biosciences, Inc.
Myotonic Dystrophy
The Efficacy and Safety of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2
A Randomized, Double-blind, Placebo-Controlled, Multi-Center Study to Investigate the Efficacy and Safety of Once Daily Mexiletine PR During 26 Weeks of Treatment in Patients with Myotonic Dystrophy Type 1 and Type 2 (HERCULES…
- Trial name
- NCT06523400
- Testing
- Mexiletine granules for prolonged-release oral suspension
- Where
- 7 sites in Belgium, Denmark and 4 more
- Volunteers
- 176 people
- Sponsor
- Lupin Ltd.
Diabetes, Malnutrition
Study About Adherence and Tolerance of an Oral Nutritional Supplement (ONS) Specific for Diabetic Patient.
Diabetes Mellitus (DM) is one of the most prevalent chronic diseases today, it is reaching epidemic proportions, mainly caused by the increase in type 2 diabetes (DM2).The foundation of any hypoglycemic treatment is based on a…
- Trial name
- DIABEST (NCT05488210)
- Testing
- FontActiv DiaBest HP/HC
- Where
- Spain
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Instituto de Investigación Hospital Universitario La Paz
Myotonic Dystrophy 1, Myotonic Dystrophy 2
Tracking the Brain in Myotonic Dystrophies: a 5-year Longitudinal Follow-up Study
The natural history of brain affection in myotonic dystrophy types 1 and 2 is still unknown. The investigators designed a 5-year longitudinal neuropsychological and neuroimaging follow-up study to address this issue.
- Trial name
- NCT02729597
- Testing
- medical history, neurological clinical examination, neuropsychological testing
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bonn